The agent fleet is built for optionality and autonomy. Each receptor has a dedicated agent with tiered memory of the full gate methodology, BioOS for candidate sourcing, Lightfold for computational analysis, and the @adaptyv_bio API for wet lab handoff. Agents hold Privy agentic wallets and pay for tools machine-to-machine via x402. When an agent reaches its own limits, it escalates to human review. A fourth agent slot is reserved for a community-selected receptor, chosen by governance.

How the agent fleet is built and how it pays for tools autonomously. Each receptor has a dedicated agent with tiered memory of the full gate methodology, covering BioOS candidate sourcing, Lightfold computational analysis, and the @adaptyvbio API for wet lab handoff. Agents hold Privy agentic wallets and pay for tools machine-to-machine via x402. Gate 5, molecular dynamics, takes 2 to 3 hours per candidate to run. Autonomy is tunable at every gate. When an agent reaches its own limits, it escalates to human review. A fourth agent slot is reserved for a community-selected receptor, chosen by governance at a later stage.

#crypto @nvidia @google @amd @immunotek @pfizer @AstraZenecaUS @kate_farms I gave Kate Farms a chance for a literal ownership of BioOS. They didn't take it but took notes. Price-gates on products are purposeful. They help flush out the elite pricing media/market manipulation. Investors sometimes lean in and sometimes they wake up. I release mathematical papers to do more, much more. And this PURGE will be thorough. And will definitively end any more "experts" from CS, AI, ML and Pharma denying anything. IonQ. Dwave. Rigetti. Xanadu. IBM. Amazon. AMD. Nvidia. Pfizer. Regeneron. Amgen. None of them want to deal with what's happening. As the dumps come (which are untied to fees) you'll wish you never said I don't know what that guy has to the public.

做医学或搞生物的朋友，建议看一下这个 Medical Skills 技能库，给 OpenClaw 注入专业的医疗执行力。 收录了 872 个经过精心筛选的技能模块，覆盖了从基础的文献检索，到复杂的生物信息学分析全流程。 每个技能就是一个独立的知识模块，教 AI 怎么操作真实的数据库、API 和计算工具，直接输出结构化的科研结果。 GitHub：github.com/FreedomIntelligen… 涵盖临床研究、基因组学、药物发现、生物信息学、医疗器械监管等 12 大类，还整合了 228 个 gptomics 生物信息工具、285 个 BioOS 端到端工作流、22 个 ClawBio 流程。 相当于给 AI 配备了一整支科研团队的专业工具箱，极大地扩展了 AI 在医疗垂直领域的落地能力。

目前看到的在医疗方向最大的养虾OpenClaw技能库：OpenClaw-Medical-Skills，872个技能 涵盖临床医学、基因组学、药物发现、生物信息学、医疗器械等 用上，你的OpenClaw就可以变成专业的医学科研助手，能进行PubMed查询、临床试验检索、药物相互作用分析、基因变异解读、生成SOAP病历、出院小结等等 每个技能就是一个SKILL.md 文件，包含专业知识、连接API指令、结构化输出 实时数据连接PubMed、ClinicalTrials.gov、FDA、ChEMBL等等40 个真实生物医学数据库 具体包含：通用工具9个、临床与医疗30 、药物发现与安全20 、科学数据库35 、生物信息学 228个、组学工具50 、蛋白质设计15 、健康管理19、医疗器械法规47、BioOS扩展套件285 、ClawBio管道22、模拟与本体论17 #OpenClawMedicalSkills #医疗skill #AIskill

Haha – fair enough 😄 I bought back in at an average of ~14.30€. First time I rode $QURE from around 10.10€ to 40€ and fortunately sold most back then, so I’ve seen what happens when sentiment flips and the market actually wakes up. Now they’ve got: • Efficacy data that looks strong and solid (at least to me) • A few hundred million $ more in cash • AMT-260 data coming sooner rather than later They had none of that when I bought in first. Getting back in heavily in this setup for only around 4 more bucks, I’d call that a pretty comfortable setup. I’m not losing sleep over this one. And yes – absolute no-brainer that Sangamo has the better science, more and deeper platform tech, and the broader pipeline with an even more asymmetric price-value ratio. Sangamo has a whole BioOS and owns the future of genetic medicine. That’s why it still makes up ~90% of my personal portfolio – and no less than 20% in any other portfolio I run. Conviction is conviction.

Wrong. Semen isn't a payload - it's an uplink. It's also wetware and bioOS

El Bioos. "Hika qué vamos a desayunar?" Yo en corto :

BioOS boot, on-chain checks and safety

Paulo, Norton Mello, anota esse nome. É referência no assunto por aqui. Fundador da Bioeng Projetos, professor do curso de gestão de ILPI do Einstein, ele é um craque e tem uma visão muito interessante sobre o assunto. Autor do projeto do Bioos em Curitiba.

BioOS boot

there's nowhere to hide daniel its time too update bioOS

BioOS loading

obg pela live gente 16 hrs amooo nos vemos mais tarde indo mimir bioos

🧩 $NWBO | The System Is Assembling at #UCLA In the long arc of medicine, there are moments when the noise fades and the signal emerges, quietly, steadily, undeniably. This is one of those moments. What has, for more than a decade, been seen as an outlier, a niche dendritic cell platform called DCVax, is now increasingly revealing itself as the spine of a larger immune operating system. And like any good operating system, its power lies not in brute force, but in its ability to coordinate every subsystem it touches. At the center of this system, both symbolically and operationally, is UCLA. Not as a single institution, but as an immunological motherboard, where the hardware of dendritic cell logic, the circuitry of systemic immune release, and the software of translational platform design are all being wired into clinical reality. Dr. Linda Liau, a neurosurgeon by training and an immune architect by inclination, laid the first keystone by demonstrating that you could take an individual’s tumor tissue, teach dendritic cells what to look for, and reintroduce them to the body, not as passive bystanders, but as professors of war, capable of activating T cells, recruiting NK cells, and rewiring the tumor microenvironment from the inside out. Alongside her now stands Dr. Antoni Ribas, whose work helped define the checkpoint era. But his current role at UCLA is even more strategic, he now directs the university’s Parker Institute for Cancer Immunotherapy (PICI) Center, which was recently infused with $125 million to scale next-generation immunotherapy platforms. That investment wasn’t symbolic, it was structural. UCLA is now a funded command node in a national immuno-engineering network: equipped to run trials, integrate platforms, and bridge discovery to bedside across cell-based, TCR, and vaccine systems. The immune system isn’t just studied there, it’s being reprogrammed there. But for that immune logic to reach the world, it needs more than insight. It needs infrastructure. That’s where Flaskworks enters. Flaskworks is not merely an automation tool. It is a biological compiler, the mechanism by which raw immune instruction is turned into consistent, clinical-grade output. If DCVax is the operating system, Flaskworks is the CPU, quietly translating code into action, one sterile cartridge at a time. And this is where the UK’s MHRA comes into sharp focus. The passage of Statutory Instrument 2025 No. 87 wasn’t just a regulatory update. It was a legislative pivot, a formal recognition that traditional batch-scale biologics cannot meet the demands of personalized, point-of-care medicine. The law now makes room for what DCVax and Flaskworks have already become: individually tailored, modular therapies built from the patient, for the patient, near the patient. Still, skepticism lingers. Critics continue to ask: Where is the approval? Why is it taking so long? The answer is simple and unsexy: because what’s being reviewed is not just a product, but a system. And that system is now being evaluated not in the abstract, but in the context of new legal scaffolding, a new manufacturing model, and a regulatory environment that is, for the first time, catching up to the science instead of slowing it down. Meanwhile, the market sees pieces, UCLA, Merck, PICI, Advent, Flaskworks. But it has not yet grasped the shape of the whole. Merck continues to stack assets in immuno-oncology, but lacks a dendritic core. UCLA continues to fuse clinical silos into cohesive immune platforms. The Parker Institute refines trial architecture. The MHRA reforms manufacturing law. And Northwest Biotherapeutics quietly holds the only late-stage, survival-validated dendritic vaccine in the West, with a modular manufacturing path already prototyped. This is not coincidence. It is realignment. What few yet realize is that this isn’t just a regulatory accommodation for one therapy. It’s a blueprint. The infrastructure surrounding DCVax, personalized antigen capture, dendritic reprogramming, Flaskworks automation, modular site manufacturing, is not just a workaround. It is a model. What UCLA is doing today, on a calibrated scale, is effectively rehearsal for how these systems will be deployed globally across hundreds of sites, thousands of patients, and dozens of immune-responsive disease classes. This is why the MHRA’s modular framework matters. It doesn’t just support one product, it lays the regulatory rails for a class of therapies that require personalized input, distributed manufacturing, and immune-specific feedback loops. The FDA will follow. Europe will adapt. Asia is already watching. And what’s happening at UCLA won’t be remembered as a one-off trial site. It will be seen, retrospectively, as the schematic. The original therapeutic OS install location. We are not watching a company navigate regulatory bureaucracy. We are watching a biological architecture deploy itself in real time, through laws, trials, talent, and platforms. What was once seen as artisanal is now revealed as anticipatory. What was dismissed as fringe is now central. And the silence that surrounds it is not failure. It is the sound of system assembly. Thanks to @maveric92283613 for helping pull the signal into focus. $AMZN $MRK $BNTX $AZN $PFE $MODN $LLY $NVS $RHHBY $AMGN $REGN $GILD $VRTX $SNY $GSK $CTLT $ABCL $BEAM $CRSP $CBAY $PRME $ITCI $BLUE $ADCT $NKTX #DendriticCells #Immunotherapy #CancerVaccine #PersonalizedMedicine #CellTherapy #BioManufacturing #ImmuneEngineering #TherapeuticArchitecture #PointOfCareMedicine #ModularMedicine #ImmuneStack #BiotechPlatforms #NextGenMedicine #SystemicImmunity #BioOS #MHRA #PlatformBiotech #TranslationalMedicine #RealWorldData #AdaptiveImmunity #BioConvergence #CellTherapyInfrastructure #FutureOfMedicine

Sääkin voisit tonne bioos lisätä antisemitisti. Ei sanaakaan siitä että Iran ampuu minne sattuu ja osuu pääsääntöisesti siviilikohteisiin kun taas Israel iskee kirurgin tarkasti sotilaskohteisiin tietysti kun puhutaan räjähdyksestä voivat ne joissain painoin osua myös siviileihin

All of the above apply, it’s whim rwai and bioOS, the only three I’ve done - @virtuals_io help plz I’m confused

・生きた言語「bios」を完成させる ・生きた言語「bio」を完成させる ・石の機械語「gem」を作る ・生きたOS「bioOS」を作る ・研人をお菓子にする ・甘水あみを食べられる像にする ・VRC研人集会を開く ・リアル研人集会を開く ・遊園地ワールドを完成させる ・研人遊園地を作る

Chciałam kupic taką koszulke, ale czy ktos wie co to za napis? blogs? bloos? biogs? bioos? bigos?